Read more here:

Bluejay Therapeutics Advances in Hepatitis B and D Trials: Successfully Completes BJT-778 Phase 1a Study and Begins Phase 1b Trial Enrollment

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh